Product Description
Praziquantel is the drug of choice for the treatment of all forms of schistosomiasis. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12811543/)
Mechanisms of Action: Calcium Channel Opener
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Brazil | Canada | Chile | China | Colombia | Cyprus | Czech | Egypt | European Medicines Agency | France | Germany | Greece | Hong Kong | India | Jordan | Korea | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Singapore | Slovenia | South Africa | Taiwan | Thailand | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Clonorchiasis | Opisthorchiasis | Schistosomiasis | Schistosomiasis mansoni
Known Adverse Events: Dizziness | Headache | Urticaria
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|